Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2024 Jun 1;52(6):e314-e322.
doi: 10.1097/CCM.0000000000006227. Epub 2024 Feb 16.

Comparison of Different Treatments of Persistent Pulmonary Hypertension of the Newborn: A Systematic Review and Network Meta-Analysis

Qiang Fei  1 , Jiarong Pan  1 , Feizhou Zhang  2 , Yu Lin  1 , Tianming Yuan  1
Affiliations
Comparative Study

Comparison of Different Treatments of Persistent Pulmonary Hypertension of the Newborn: A Systematic Review and Network Meta-Analysis

Qiang Fei et al. Crit Care Med. .

Abstract

Objectives: Persistent pulmonary hypertension of the newborn (PPHN) is a life-threatening disease. Despite being considered the gold standard treatment scheme, inhaled nitric oxide (iNO) is not readily available in settings with limited resources. Therefore, in recent years, research on related drugs is being actively pursued. Herein, we aimed to use random-effects network meta-analysis to evaluate the efficacy and associated mortality of different PPHN therapies.

Data sources: We electronically searched the PubMed, Embase, and Cochrane Library for data up to January 27, 2023.

Study selection: Randomized controlled trials involving neonates with PPHN assessing efficacy and mortality of various treatments.

Data extraction: Details of study population, treatments, and outcomes were extracted.

Data synthesis: Direct pairwise comparisons and a network meta-analysis was performed under random effects. The ranking probability was further assessed based on the surface under the cumulative ranking curve (SUCRA). We analyzed 23 randomized clinical trials involving 902 newborns with PPHN. Sixteen different treatment strategies were compared with each other and conventional therapy (CON). A median concentration of 10-20 parts per million (ppm) iNO (MNO) coupled with sildenafil orally administered at a dose of 1-3 mg/kg/dose every 6-8 hours (OSID) demonstrated the best efficacy (MNO + OSID vs. CON: odds ratio [OR] = 27.53, 95% CI, 2.36-321.75; SUCRA = 0.818, ranking first; moderate quality). OSID combined with milrinone administered IV also performed well in terms of efficacy (OSID + milrinone vs. CON: OR = 25.13, 95% CI = 1.67-377.78; SUCRA = 0.811, ranking second; low quality) and mortality reduction (CON vs. OSID + milrinone: OR = 25.13, 95% CI = 1.67-377.78; SUCRA = 0.786, ranking last; low quality).

Conclusions: MNO + OSID is the most effective PPHN treatment. If iNO is not available, OSID + milrinone is preferred.

PubMed Disclaimer

Conflict of interest statement

The authors have disclosed that they do not have any potential conflicts of interest.

Comment in

References

    1. Sharma V, Berkelhamer S, Lakshminrusimha S: Persistent pulmonary hypertension of the newborn. Matern Health Neonatol Perinatol. 2015; 1:14
    1. Fuloria M, Aschner JL: Persistent pulmonary hypertension of the newborn. Semin Fetal Neonatal Med. 2017; 22:220–226
    1. Nakwan N, Jain S, Kumar K, et al.: An Asian multicenter retrospective study on persistent pulmonary hypertension of the newborn: Incidence, etiology, diagnosis, treatment and outcome. J Matern Fetal Neonatal Med. 2020; 33:2032–2037
    1. Evers PD, Critser PJ, Cash M, et al.: Cost-utility of sildenafil for persistent pulmonary hypertension of the newborn. Am J Perinatol. 2021; 38:1505–1512
    1. INO Theraputics: INOmax®—Nitric Oxide Gas Prescribing Information. Available at: https://www.inomax.com/downloads/Inomax-PI.pdf . Accessed April 1, 2023

MeSH terms

LinkOut - more resources